Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8931

Phenylbutazone: Target Organs and Levels of Evidence for TR-367

Toxicology and Carcinogenesis Studies of Phenylbutazone (CASRN 50-33-9) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
Phenylbutazone
50-33-9		03/13/1989Gavage
R: 0, 50, 100, M: 0, 150, 300 MG/KG/50 PER GROUP		T.S.I. Mason Laboratories, Inc.

Levels of Evidence

Male Rats: Equivocal Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: ADENOMA 0/50 0/49 3/50 OR CARCINOMA 0/50 1/49 0/50 COMBINED 0/50 1/49 3/50
Non-Neoplastic Lesions
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; PAPILLA, NECROSIS 1/50 10/49 24/50; COLLECTING TUBULE, MINERALIZATION 5/50 10/49 35/50
Female Rats: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Transitional Cell: CARCINOMA 0/50 0/50 2/50
May Have Been Related
  • Kidney Tubular Cell: ADENOMA (STEP SECTIONS) 0/50 3/50 1/50 OR CARCINOMA 0/50 1/50 0/50 COMBINED 0/50 4/50 1/50
Non-Neoplastic Lesions
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY; PAPILLA, NECROSIS 0/50 18/50 35/50; COLLECTING TUBULE, MINERALIZATION 3/50 31/50 46/50
Male Mice: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 8/50 12/50 24/50 OR CARCINOMA 8/50 4/50 11/50 COMBINED 16/50 14/50 31/50
Female Mice: No Evidence